

Mulas Olga

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5978341/publications.pdf>

Version: 2024-02-01

32
papers

422
citations

933447

10
h-index

752698

20
g-index

32
all docs

32
docs citations

32
times ranked

595
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Residual Peripheral Blood CD26+ Leukemic Stem Cells in Chronic Myeloid Leukemia Patients During TKI Therapy and During Treatment-Free Remission. <i>Frontiers in Oncology</i> , 2018, 8, 194. | 2.8 | 84 |
| 2 | Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart. <i>Hematological Oncology</i> , 2019, 37, 296-302. | 1.7 | 53 |
| 3 | Killer immunoglobulin-like receptors can predict TKI treatment-free remission in chronic myeloid leukemia patients. <i>Experimental Hematology</i> , 2015, 43, 1015-1018.e1. | 0.4 | 51 |
| 4 | Homozygosity for killer immunoglobulin-like receptor haplotype A predicts complete molecular response to treatment with tyrosine kinase inhibitors in chronic myeloid leukemia patients. <i>Experimental Hematology</i> , 2013, 41, 424-431. | 0.4 | 32 |
| 5 | Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: Identification of risk factors and the role of prophylaxis. <i>American Journal of Hematology</i> , 2018, 93, E159-E161. | 4.1 | 26 |
| 6 | Long-term mortality rate for cardiovascular disease in 656 chronic myeloid leukaemia patients treated with second- and third-generation tyrosine kinase inhibitors. <i>International Journal of Cardiology</i> , 2020, 301, 163-166. | 1.7 | 21 |
| 7 | Recurrent arterial occlusive events in patients with chronic myeloid leukemia treated with second- and third-generation tyrosine kinase inhibitors and role of secondary prevention. <i>International Journal of Cardiology</i> , 2019, 288, 124-127. | 1.7 | 19 |
| 8 | Ruxolitinib does not impair humoral immune response to COVID-19 vaccination with BNT162b2 mRNA COVID-19 vaccine in patients with myelofibrosis. <i>Annals of Hematology</i> , 2022, 101, 929-931. | 1.8 | 19 |
| 9 | Low-density lipoprotein (LDL) levels and risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib. <i>Annals of Hematology</i> , 2021, 100, 2005-2014. | 1.8 | 14 |
| 10 | HLA-G molecules and clinical outcome in Chronic Myeloid Leukemia. <i>Leukemia Research</i> , 2017, 61, 1-5. | 0.8 | 12 |
| 11 | Incidence and evaluation of predisposition to cardiovascular toxicity in chronic myeloid leukemia patients treated with bosutinib in the real-life practice. <i>Annals of Hematology</i> , 2019, 98, 1885-1890. | 1.8 | 10 |
| 12 | Risk and Response-Adapted Treatment in Multiple Myeloma. <i>Cancers</i> , 2020, 12, 3497. | 3.7 | 10 |
| 13 | Renin angiotensin system inhibitors reduce the incidence of arterial thrombotic events in patients with hypertension and chronic myeloid leukemia treated with second- or third-generation tyrosine kinase inhibitors. <i>Annals of Hematology</i> , 2020, 99, 1525-1530. | 1.8 | 9 |
| 14 | Metabolomic Analysis of Patients with Chronic Myeloid Leukemia and Cardiovascular Adverse Events after Treatment with Tyrosine Kinase Inhibitors. <i>Journal of Clinical Medicine</i> , 2020, 9, 1180. | 2.4 | 9 |
| 15 | Conditioning Regimens in Patients with β^2 -Thalassemia Who Underwent Hematopoietic Stem Cell Transplantation: A Scoping Review. <i>Journal of Clinical Medicine</i> , 2022, 11, 907. | 2.4 | 9 |
| 16 | Arterial Hypertension and Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A Systematic Review and Meta-Analysis. <i>Frontiers in Pharmacology</i> , 2021, 12, 674748. | 3.5 | 7 |
| 17 | Low low-density lipoprotein (LDL), cholesterol and triglycerides plasma levels are associated with reduced risk of arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life. A Campus CML study. <i>Blood Cancer Journal</i> , 2020, 10, 66. | 6.2 | 6 |
| 18 | Increased incidence of infection in patients with myelofibrosis and transfusion-associated iron overload in the clinical setting. <i>International Journal of Hematology</i> , 2020, 111, 614-618. | 1.6 | 6 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Prognostic Factors for Overall Survival In Chronic Myeloid Leukemia Patients: A Multicentric Cohort Study by the Italian CML GIMEMA Network. <i>Frontiers in Oncology</i> , 2021, 11, 739171. | 2.8 | 6 |
| 20 | Pro-Inflammatory and Pro-Oxidative Changes During Nilotinib Treatment in CML Patients: Results of a Prospective Multicenter Front-Line TKIs Study (KIARO Study). <i>Frontiers in Oncology</i> , 2022, 12, 835563. | 2.8 | 6 |
| 21 | Peripheral Blood CD26+ Leukemia Stem Cells Monitoring in Chronic Myeloid Leukemia Patients from Diagnosis to Response to TKIs: Interim Results of a Multicenter Prospective Study (PROSPECTIVE) <i>Tj ETQq1 1 0.78434 4 rgBT4Overlo</i> | | |
| 22 | The association between Major Depressive Disorder and premature death risk in hematologic and solid cancer: a longitudinal cohort study. <i>Journal of Public Health Research</i> , 2021, 10, . | 1.2 | 2 |
| 23 | Metabolomics Profile of Patients with Chronic Myeloid Leukemia and Cardiovascular Adverse Events after Treatment with Tyrosine Kinase Inhibitors. <i>Blood</i> , 2019, 134, 4144-4144. | 1.4 | 2 |
| 24 | Should be a Third Dose of BNT162b2 mRNA COVID-19-Vaccine Administered in Patients with Myelofibrosis Under Ruxolitinib?. <i>Blood</i> , 2021, 138, 2573-2573. | 1.4 | 2 |
| 25 | Favorable outcome of chronic myeloid leukemia co-expressing e13a2 and e14a2 transcripts, treated with nilotinib. <i>Hematological Oncology</i> , 2020, 38, 607-610. | 1.7 | 1 |
| 26 | Arterial Occlusive Events in Chronic Myeloid Leukemia Patients Treated with Ponatinib in the Real-Life Practice: Prophylaxis and Identification of Risk Factors. <i>Blood</i> , 2018, 132, 3006-3006. | 1.4 | 1 |
| 27 | Pro-Inflammatory and Pro-Oxidative Changes during Nilotinib Treatment in CML Patients: Results of a Prospective Multicenter Front-Line TKIs Study (KIARO Study). <i>Blood</i> , 2021, 138, 1479-1479. | 1.4 | 1 |
| 28 | Rituximab Monotherapy or in Combination with Bendamustine Is Not Inferior to Rituximab-CHOP Regimen in the Treatment of Patients with Splenic Marginal Zone Lymphoma in the Real Life. <i>Acta Haematologica</i> , 2021, 144, 322-326. | 1.4 | 0 |
| 29 | Increased Incidence of Infection in Patients with Myelofibrosis and Transfusion-Associated Iron Overload: A Monocentric Experience. <i>Blood</i> , 2019, 134, 4186-4186. | 1.4 | 0 |
| 30 | Analysis of Early Events during the First Year of Tyrosine Kinase Inhibitor Therapy in Patients with Chronic Phase - Chronic Myeloid Leukemia: A "Campus CML" Study. <i>Blood</i> , 2021, 138, 1487-1487. | 1.4 | 0 |
| 31 | Predictive Factors for Overall Survival in Chronic Myeloid Leukemia Patients: An Analysis By the Gimema Cml Italian Study. <i>Blood</i> , 2020, 136, 47-48. | 1.4 | 0 |
| 32 | Low Cholesterol, Low-Density Lipoprotein (LDL) and Triglycerides Plasma Levels Are Associated with Lower Risk of Arterial Occlusive Events in Chronic Myeloid Leukemia Patients Treated with Nilotinib. <i>Blood</i> , 2020, 136, 8-9. | 1.4 | 0 |